Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Other financing activities (2021 - 2025)

Historic Other financing activities for InMed Pharmaceuticals (INM) over the last 5 years, with Q3 2025 value amounting to $137178.0.

  • InMed Pharmaceuticals' Other financing activities fell 2848.76% to $137178.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $354193.0, marking a year-over-year increase of 2609.85%. This contributed to the annual value of $883978.0 for FY2025, which is 5724.92% up from last year.
  • As of Q3 2025, InMed Pharmaceuticals' Other financing activities stood at $137178.0, which was down 2848.76% from $191824.0 recorded in Q3 2024.
  • In the past 5 years, InMed Pharmaceuticals' Other financing activities registered a high of $1.1 million during Q3 2021, and its lowest value of $25191.0 during Q3 2023.
  • For the 5-year period, InMed Pharmaceuticals' Other financing activities averaged around $384307.3, with its median value being $191824.0 (2024).
  • In the last 5 years, InMed Pharmaceuticals' Other financing activities tumbled by 9559.03% in 2023 and then surged by 66147.83% in 2024.
  • Over the past 5 years, InMed Pharmaceuticals' Other financing activities (Quarter) stood at $179118.0 in 2021, then skyrocketed by 282.23% to $684650.0 in 2022, then plummeted by 96.32% to $25191.0 in 2023, then soared by 661.48% to $191824.0 in 2024, then dropped by 28.49% to $137178.0 in 2025.
  • Its Other financing activities was $137178.0 in Q3 2025, compared to $191824.0 in Q3 2024 and $25191.0 in Q3 2023.